首页 > 最新文献

HemaSphere最新文献

英文 中文
Are we ready for disease modification in myeloproliferative neoplasms? 我们准备好改变骨髓增生性肿瘤的病情了吗?
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-09-15 DOI: 10.1002/hem3.70003
Claire N. Harrison
<p>Myeloproliferative neoplasms (MPN) are chronic myeloid diseases characterized by clinical heterogeneity and disordered JAK/STAT signaling. For the purposes of this perspective, the three common MPN, essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), will be considered.<span><sup>1</sup></span> These are closely related conditions as recognized by William Dameshek in 1951; in recent decades, multiple scientific and clinical advances have improved our understanding of their pathophysiology and outcomes for patients (<i>vida infra</i>). Risks for these patients include reduced life expectancy due to thrombosis, hemorrhage, and disease transformation (Figure 1). However, while for other myeloid malignancies, notably chronic and acute myeloid leukemia, disease modification is largely measured by morphological and molecular responses correlating with survival benefits. Currently, the situation for MPN management is perceived to be less advanced. This may in part be due to the relatively late designation of MPN as a malignancy.</p><p>Here, we shall define disease modification as treatments or interventions that affect the underlying pathophysiology of the disease and have beneficial outcomes on the clinical course and address the question: “Are we ready for disease modification in MPN?”</p><p>Major clinical events for patients with MPN as stated above are thrombosis, hemorrhage, and disease transformation; particularly to myelofibrosis, these require long-term studies to assess. But in recent years, at least for treating myelofibrosis, attention has also been focused on splenomegaly and the impact of disease-related symptoms on quality of life as relevant endpoints.</p><p>Specifically, for ET and PV treatment, algorithms focus on risk stratification based on perceived thrombotic and, to a lesser extent, hemorrhagic risk but not on reducing disease transformation. Therapeutic approaches focus on addressing modifiable factors from the perspective of vascular disease; for example, smoking, obesity, and hypertension; venesection or phlebotomy in PV; followed by antiplatelet drugs and then, in selected patients, cytoreductive therapy.<span><sup>2</sup></span> The aim of cytoreductive therapy is thus to reduce thrombosis or hemorrhage. In PV, these approaches have been shown to reduce the risk of thrombosis. For example, in the CYTOPV study, hematocrit (HCT) target <45% or 45%–50% at a median follow-up of 31 months; thrombotic events or deaths from vascular causes: <45% HCT (2.7%); 45%–50% HCT (9.8%).<span><sup>3</sup></span> Second, in the ECLAP study where low-dose aspirin compared to placebo was shown to reduce the risk of the end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes: (relative risk, 0.40; 95% confidence interval, 0.18–0.91; <i>p</i> = 0.03).<span><sup>4</sup></span></p><p>In MF, the advent of JAK inhibitor-based thera
也许,JAK2-ET最终可以用类似于PV的方式来管理,事实上,ISPET等预后评分认为JAK2-ET比CALR-ET有更大的血栓形成风险,尽管后者有更大的中风转化风险。未来,我们可能会区别对待 CALR-、MPL- 和 JAK2-ET。最后,关于分子反应,重要的是还要考虑克隆的复杂性,即存在一种以上的致病突变,这些突变可能与驱动突变发生在同一克隆中,也可能不发生在同一克隆中。除了脾脏、症状和分子反应外,中风疾病改变的其他潜在标志物还包括细胞因子的变化、炎症环境的变化以及使用人工智能技术对骨髓组织学的评估。其中每一项都需要大量的评估和标准化工作。考虑到脾脏反应,失去反应的时间可能很重要,因为初始脾脏体积缩小似乎与生存获益密切相关。就症状而言,我们不应该失去已经为患者带来的益处,但我们建议,需要认识到非劣效性终点可能更合适。如上所述,最近对骨髓纤维化的研究进一步质疑了目前的治疗目标,如将脾脏和症状反应作为试验终点。较新的药物可更直接地解决疾病的潜在病理生理学问题。具体来说,这些疗法目前包括突变 CALR 靶向疗法,如疫苗接种、突变 CALR 靶向抗体、双特异性药物,或许还包括 CAR-T 疗法和突变特异性 JAK2 抑制剂。这些疗法为真正改变疾病提供了令人兴奋的新机遇,但我们需要进一步了解如何衡量这种益处。有趣的是,这些疗法还可能重振有关 MPN 亚型分类的争论,使之朝着更多突变特异性方法的方向发展,Grinfeld 及其同事的研究也支持这一观点。27 在这个主要由 ET 患者组成的 MPN 队列中,Grinfeld 及其同事整理了 63 个临床和基因组变量,创建了预后模型,并生成了对患者预后的个体预测,这些预测也可用于指导治疗。重要的是,他们证明患者的预后在很大程度上受基因组变量的影响。因此,该模型的另一个意义在于,我们可以放弃 19 世纪末和 20 世纪初临床描述性定义的 MPN 实体(ET、PV、MF)。此外,该模型还提供了一个诱人的机会,即利用这些数据集生成一个真实世界中基于证据的 "数字孪生 "患者及其临床试验预测结果。目前谨慎的循证管理可以实现这一目标,例如,获得完全应答(控制血液指标和脾脏大小)可以实现无事件生存。但在未来,我们可能会对几乎所有的 PV 患者进行治疗,尤其是采用更现代、毒性更低的疗法(如鲁索利替尼或rog-pegylated 干扰素-α-2b),在标准化、最佳反应动力学等细微差别得到解决后,实现 JAK2 VAF 或分子反应降低 50%的目标。与此同时,我们还需要收集更多有关分子反应对 CALR 和 MPL 基因突变疾病是否有益的数据。对临床信息进行仔细整理和注释,再加上新疗法的发展,有望在 ET 和 MF 等异质性较强的疾病以及纤维化前骨髓纤维化等不太明确的 MPN 实体的背景下,推动可靠数据的开发,以产生更好的终点。与此同时,还有许多工作要做,这需要患者群体、临床专家、翻译科学家、制药公司、审批机构、付款人以及那些熟练掌握海量数据集的人员之间的密切合作。本图由 HemaSphere.Claire N. Harrison 支持制作:研究经费:Celgene(BMS)、Constellation、葛兰素史克、诺华。顾问角色:AbbVie、AOP、BMS、CTI、IMAGO、Incyte、Novartis、Galacteo、Geron、GSK、Incyte、Janssen、Keros、MSD、SOBI、Morphosys,并担任 HemaSphere 编辑。
{"title":"Are we ready for disease modification in myeloproliferative neoplasms?","authors":"Claire N. Harrison","doi":"10.1002/hem3.70003","DOIUrl":"https://doi.org/10.1002/hem3.70003","url":null,"abstract":"&lt;p&gt;Myeloproliferative neoplasms (MPN) are chronic myeloid diseases characterized by clinical heterogeneity and disordered JAK/STAT signaling. For the purposes of this perspective, the three common MPN, essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), will be considered.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; These are closely related conditions as recognized by William Dameshek in 1951; in recent decades, multiple scientific and clinical advances have improved our understanding of their pathophysiology and outcomes for patients (&lt;i&gt;vida infra&lt;/i&gt;). Risks for these patients include reduced life expectancy due to thrombosis, hemorrhage, and disease transformation (Figure 1). However, while for other myeloid malignancies, notably chronic and acute myeloid leukemia, disease modification is largely measured by morphological and molecular responses correlating with survival benefits. Currently, the situation for MPN management is perceived to be less advanced. This may in part be due to the relatively late designation of MPN as a malignancy.&lt;/p&gt;&lt;p&gt;Here, we shall define disease modification as treatments or interventions that affect the underlying pathophysiology of the disease and have beneficial outcomes on the clinical course and address the question: “Are we ready for disease modification in MPN?”&lt;/p&gt;&lt;p&gt;Major clinical events for patients with MPN as stated above are thrombosis, hemorrhage, and disease transformation; particularly to myelofibrosis, these require long-term studies to assess. But in recent years, at least for treating myelofibrosis, attention has also been focused on splenomegaly and the impact of disease-related symptoms on quality of life as relevant endpoints.&lt;/p&gt;&lt;p&gt;Specifically, for ET and PV treatment, algorithms focus on risk stratification based on perceived thrombotic and, to a lesser extent, hemorrhagic risk but not on reducing disease transformation. Therapeutic approaches focus on addressing modifiable factors from the perspective of vascular disease; for example, smoking, obesity, and hypertension; venesection or phlebotomy in PV; followed by antiplatelet drugs and then, in selected patients, cytoreductive therapy.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The aim of cytoreductive therapy is thus to reduce thrombosis or hemorrhage. In PV, these approaches have been shown to reduce the risk of thrombosis. For example, in the CYTOPV study, hematocrit (HCT) target &lt;45% or 45%–50% at a median follow-up of 31 months; thrombotic events or deaths from vascular causes: &lt;45% HCT (2.7%); 45%–50% HCT (9.8%).&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Second, in the ECLAP study where low-dose aspirin compared to placebo was shown to reduce the risk of the end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes: (relative risk, 0.40; 95% confidence interval, 0.18–0.91; &lt;i&gt;p&lt;/i&gt; = 0.03).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In MF, the advent of JAK inhibitor-based thera","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 9","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142234752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Informed consent is almost impossible 知情同意几乎是不可能的
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-09-15 DOI: 10.1002/hem3.70002
Louise Caldwell, Stephen P. Hibbs
<p>Informed consent underpins the practice of medicine. Beyond signing a form, the consent process provides both space and time for patients to gain a better understanding of the practicalities of the treatment and to ask questions of their clinician. If done well, informed consent can enable patient autonomy, facilitate a better understanding of the short- and long-term implications of treatments, and share power with patients in the decision-making process.</p><p>But many of us will have encountered situations where ‘informed consent’ has been recorded, yet a myeloma patient is later surprised and distressed to learn that their chemotherapy was never expected to cure them. A study of over one thousand patients on palliative chemotherapy for lung or colorectal cancer found that the majority did not understand the intent of their treatment.<span><sup>1</sup></span> While our consent practices may be acceptable within legal and bureaucratic norms, how often do patients truly understand the treatments we recommend and prescribe?</p><p>Some of the difficulty lies in the approach or capacity of the clinician. The consent process can become rushed, perfunctory and at times transactional. Even the terminology of ‘taking’ consent is telling, evoking a rushed conversation to extract a signature on a consent form so that treatment can commence.</p><p>Clinicians often draw arbitrarily sharp lines around decisions that require written consent and those that do not. The <i>written</i> component may be less important than the ‘hard stop’ it provides to clinicians, requiring a detailed conversation with the patient before proceeding with treatment. Any chemotherapy—of whatever level of intensity—requires a formal written consent process. In contrast, steroids for immune thrombocytopenia, transfusions in sickle cell disease, or anticoagulation incurs significant risk, but consent practices for these interventions are minimal or inconsistent.<span><sup>2</sup></span></p><p>Aside from hurried clinicians, patients face other challenges during consent conversations. In fraught and high-stakes situations where patients are reeling from a new diagnosis of life-limiting cancer or are overwhelmed by symptoms of their disease, the intricacies of the treatment they are being consented for may seem marginal or irrelevant. The intensity and immediacy of illness can distort a patient's ability to ‘hear’ the risks of the treatment. Some may approach treatment with complete optimism, suppressing any imagining of risk or failure. Others may be unable to perceive any sort of future whilst confronting an overwhelming present. Can a person ever truly fathom the potential risks that accompany a treatment, when hope demands they believe they will escape them?</p><p>Some consent conversations are particularly demanding to both the clinician and the patient. In UK haemato-oncology practice, patients with a new diagnosis of acute leukaemia are invited to consent to whole-genome sequen
最后,承认知情同意是困难的--有时几乎是不可能的--这就对患者的完全选择权总是优先的观念提出了挑战。许多患者并不认为临床医生是冷漠的信息传播者,也不认为自己是知情的医疗消费者,而是寻求值得信赖和关爱的人,无论采取何种治疗方法,这些人都会与他们同甘共苦。斯蒂芬-P.-希布斯(Stephen P. Hibbs)由惠康基金会(资助编号 223 500/Z/21/Z)资助的 HARP 博士研究奖学金支持。本出版物未获得任何资助。
{"title":"Informed consent is almost impossible","authors":"Louise Caldwell,&nbsp;Stephen P. Hibbs","doi":"10.1002/hem3.70002","DOIUrl":"https://doi.org/10.1002/hem3.70002","url":null,"abstract":"&lt;p&gt;Informed consent underpins the practice of medicine. Beyond signing a form, the consent process provides both space and time for patients to gain a better understanding of the practicalities of the treatment and to ask questions of their clinician. If done well, informed consent can enable patient autonomy, facilitate a better understanding of the short- and long-term implications of treatments, and share power with patients in the decision-making process.&lt;/p&gt;&lt;p&gt;But many of us will have encountered situations where ‘informed consent’ has been recorded, yet a myeloma patient is later surprised and distressed to learn that their chemotherapy was never expected to cure them. A study of over one thousand patients on palliative chemotherapy for lung or colorectal cancer found that the majority did not understand the intent of their treatment.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; While our consent practices may be acceptable within legal and bureaucratic norms, how often do patients truly understand the treatments we recommend and prescribe?&lt;/p&gt;&lt;p&gt;Some of the difficulty lies in the approach or capacity of the clinician. The consent process can become rushed, perfunctory and at times transactional. Even the terminology of ‘taking’ consent is telling, evoking a rushed conversation to extract a signature on a consent form so that treatment can commence.&lt;/p&gt;&lt;p&gt;Clinicians often draw arbitrarily sharp lines around decisions that require written consent and those that do not. The &lt;i&gt;written&lt;/i&gt; component may be less important than the ‘hard stop’ it provides to clinicians, requiring a detailed conversation with the patient before proceeding with treatment. Any chemotherapy—of whatever level of intensity—requires a formal written consent process. In contrast, steroids for immune thrombocytopenia, transfusions in sickle cell disease, or anticoagulation incurs significant risk, but consent practices for these interventions are minimal or inconsistent.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Aside from hurried clinicians, patients face other challenges during consent conversations. In fraught and high-stakes situations where patients are reeling from a new diagnosis of life-limiting cancer or are overwhelmed by symptoms of their disease, the intricacies of the treatment they are being consented for may seem marginal or irrelevant. The intensity and immediacy of illness can distort a patient's ability to ‘hear’ the risks of the treatment. Some may approach treatment with complete optimism, suppressing any imagining of risk or failure. Others may be unable to perceive any sort of future whilst confronting an overwhelming present. Can a person ever truly fathom the potential risks that accompany a treatment, when hope demands they believe they will escape them?&lt;/p&gt;&lt;p&gt;Some consent conversations are particularly demanding to both the clinician and the patient. In UK haemato-oncology practice, patients with a new diagnosis of acute leukaemia are invited to consent to whole-genome sequen","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 9","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142234751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis 口服铁蛋白抑制剂 vamifeport 可防止血色沉着病小鼠模型的肝脏铁负荷过重
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-09-12 DOI: 10.1002/hem3.147
Naja Nyffenegger, Anna Flace, Ahmet Varol, Patrick Altermatt, Cédric Doucerain, Hanna Sundstrom, Franz Dürrenberger, Vania Manolova

Hemochromatosis is an inherited iron overload condition caused by mutations that reduce the levels of the iron-regulatory hormone hepcidin or its binding to ferroportin. The hepcidin–ferroportin axis is pivotal to iron homeostasis, providing opportunities for therapeutic intervention in iron overload disorders like hemochromatosis. The aim of this study was to evaluate the efficacy of the oral ferroportin inhibitor vamifeport in the Hfe C282Y mouse model, which carries the most common mutation found in patients with hemochromatosis. A single oral dose of vamifeport lowered serum iron levels in Hfe C282Y mice, with delayed onset and shorter duration than observed in wild-type mice. Vamifeport induced transient hypoferremia by inhibiting ferroportin and resulted in a feedback regulation of liver Hamp in wild-type mice, which was absent in Hfe C282Y mice, reflecting the dysregulated systemic iron sensing in this hemochromatosis model. Chronic dosing with vamifeport led to sustained serum and liver iron reductions in Hfe C282Y mice, as well as markedly reducing liver Hamp expression in Hfe C282Y mice, suggesting distinct regulation of liver Hamp expression following acute or continuous iron restriction via vamifeport. At the tested dose, vamifeport retained its activity when combined with phlebotomy and did not significantly interfere with liver iron removal by phlebotomy in Hfe C282Y mice. These data demonstrate that chronic vamifeport treatment significantly reduces serum iron levels and prevents liver iron loading in the Hfe C282Y mouse model of hemochromatosis, thus providing preclinical proof of concept for the efficacy of vamifeport in hemochromatosis with or without phlebotomy.

血色素沉着病是一种遗传性铁超载疾病,由基因突变导致铁调节激素 hepcidin 或其与 ferroportin 结合水平降低引起。血色素-铁皮质素轴对铁平衡至关重要,为治疗血色素沉着病等铁超负荷疾病提供了机会。本研究旨在评估口服铁皮质素抑制剂vamifeport对Hfe C282Y小鼠模型的疗效。与野生型小鼠相比,单次口服剂量的vamifeport可降低Hfe C282Y小鼠的血清铁水平,且起效时间更晚,持续时间更短。瓦米福肽通过抑制铁蛋白诱导一过性低铁血黄素,并导致野生型小鼠肝脏 Hamp 的反馈调节,而 Hfe C282Y 小鼠不存在这种反馈调节,这反映了这种血色病模型的全身铁感应失调。长期服用伐米福特可使 Hfe C282Y 小鼠血清和肝脏中的铁含量持续降低,并显著降低 Hfe C282Y 小鼠肝脏中 Hamp 的表达,这表明通过伐米福特进行急性或持续铁限制后,肝脏中 Hamp 的表达会受到不同程度的调节。在测试剂量下,伐米福特与抽血疗法联合使用时仍能保持其活性,并且不会明显干扰 Hfe C282Y 小鼠通过抽血疗法清除肝脏铁的过程。这些数据表明,在 Hfe C282Y 血色素沉着病小鼠模型中,长期服用伐米福特可显著降低血清铁水平并防止肝脏铁负荷,从而为伐米福特对血色素沉着病的疗效提供了临床前概念证明,无论是否进行抽血疗法。
{"title":"The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis","authors":"Naja Nyffenegger,&nbsp;Anna Flace,&nbsp;Ahmet Varol,&nbsp;Patrick Altermatt,&nbsp;Cédric Doucerain,&nbsp;Hanna Sundstrom,&nbsp;Franz Dürrenberger,&nbsp;Vania Manolova","doi":"10.1002/hem3.147","DOIUrl":"https://doi.org/10.1002/hem3.147","url":null,"abstract":"<p>Hemochromatosis is an inherited iron overload condition caused by mutations that reduce the levels of the iron-regulatory hormone hepcidin or its binding to ferroportin. The hepcidin–ferroportin axis is pivotal to iron homeostasis, providing opportunities for therapeutic intervention in iron overload disorders like hemochromatosis. The aim of this study was to evaluate the efficacy of the oral ferroportin inhibitor vamifeport in the <i>Hfe</i> C282Y mouse model, which carries the most common mutation found in patients with hemochromatosis. A single oral dose of vamifeport lowered serum iron levels in <i>Hfe</i> C282Y mice, with delayed onset and shorter duration than observed in wild-type mice. Vamifeport induced transient hypoferremia by inhibiting ferroportin and resulted in a feedback regulation of liver <i>Hamp</i> in wild-type mice, which was absent in <i>Hfe</i> C282Y mice, reflecting the dysregulated systemic iron sensing in this hemochromatosis model. Chronic dosing with vamifeport led to sustained serum and liver iron reductions in <i>Hfe</i> C282Y mice, as well as markedly reducing liver <i>Hamp</i> expression in <i>Hfe</i> C282Y mice, suggesting distinct regulation of liver <i>Hamp</i> expression following acute or continuous iron restriction via vamifeport. At the tested dose, vamifeport retained its activity when combined with phlebotomy and did not significantly interfere with liver iron removal by phlebotomy in <i>Hfe</i> C282Y mice. These data demonstrate that chronic vamifeport treatment significantly reduces serum iron levels and prevents liver iron loading in the <i>Hfe</i> C282Y mouse model of hemochromatosis, thus providing preclinical proof of concept for the efficacy of vamifeport in hemochromatosis with or without phlebotomy.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 9","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Battle of the sexes: Understanding donor:recipient sex differences in transplantation biology 性别之战:了解移植生物学中供体与受体的性别差异
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-09-10 DOI: 10.1002/hem3.70000
David G. Kent
<p>Studying hematopoietic stem cell (HSC) function is most powerfully done with serial transplantation assays that can formally demonstrate the hallmark functional properties of durability, self-renewal, and multilineage differentiation capacity. Transplantation assays have taken many forms over the decades to provide evidence of HSC function, with mouse:mouse studies representing the bulk of studies to date. Competing for the limelight as a “gold standard” assay for nearly as long, however, is the human HSC:mouse recipient xenotransplantation assay, which has been powerfully used to help define the relative function of both normal HSCs and HSCs isolated from leukemia patients. The latter presents the most urgent need for establishing robust assays in the hematological community. It represents the opportunity to study the function of HSCs isolated from patients with the diseases that we are trying to cure. While there are a number of studies that have used human:human transplantations in clinical settings to study the dynamics of HSCs,<span><sup>1, 2</sup></span> the ability to characterize leukemic HSCs at a detailed molecular level and to treat them with experimental compounds to potentially modify those clonal dynamics for therapeutic purposes remains extremely limited. This is where the xenotransplantation assay comes to the fore, but defining an agreed set of standards in the field is a complex business, and a recent study in <i>HemaSphere</i> by Mian et al. sheds some light on one of the key factors in transplantation biology—sex differences.<span><sup>3</sup></span></p><p>Sex differences in transplantation have been known about for some time, although the studies do not always agree on the how's and why's of these differences. Single HSC transplantation studies in mouse:mouse donor:recipient pairs showed that male HSCs did not perform well in female recipients, potentially due to a weak antigen coded for by the Y chromosome.<span><sup>4</sup></span> Another study,<span><sup>5</sup></span> in human:mouse xenotransplants, showed that female immunodeficient NOD/SCID/IL-2Rgc-null (NSG) mice were far superior as recipients of human cells with increases in both engraftment and proliferation of human HSCs (and this was also evidenced at the single-cell level). In this latter study, two potential reasons were speculated: first, that “female NSG mice might be more immunodeficient than males,” and second that “sex-associated factors, such as steroid hormones, can positively or negatively regulate human HSCs.” It is clear that sex matters, but with the emergence of new immunodeficient models and a general lack of comparative studies between male and female recipients, it is difficult to articulate a set of field recommendations for how to undertake xenotransplantation experiments with precious patient samples.</p><p>The recently published study by Mian et al.<span><sup>3</sup></span> goes some way to addressing this. Using various immunodeficient mou
最后,作者对移植到男性和女性受者体内的正常造血干细胞的成熟细胞产量和静止状态进行了比较,并指出成熟细胞产生的有趣模式也取决于供体和受体的性别。这些发现共同强调了供体:受体性别匹配在移植研究中的重要性,同时也强调了在研究报告中报告受体性别的必要性。这进一步表明,应在移植生物学和临床试验设计方面进一步探索性别特异性机制,确保造血干细胞及其后代的生物学特性存在性别特异性差异,并将其考虑在内。在未来几年中,我们将非常关注这些观察结果如何在实验设计和报告中得到应用。
{"title":"Battle of the sexes: Understanding donor:recipient sex differences in transplantation biology","authors":"David G. Kent","doi":"10.1002/hem3.70000","DOIUrl":"https://doi.org/10.1002/hem3.70000","url":null,"abstract":"&lt;p&gt;Studying hematopoietic stem cell (HSC) function is most powerfully done with serial transplantation assays that can formally demonstrate the hallmark functional properties of durability, self-renewal, and multilineage differentiation capacity. Transplantation assays have taken many forms over the decades to provide evidence of HSC function, with mouse:mouse studies representing the bulk of studies to date. Competing for the limelight as a “gold standard” assay for nearly as long, however, is the human HSC:mouse recipient xenotransplantation assay, which has been powerfully used to help define the relative function of both normal HSCs and HSCs isolated from leukemia patients. The latter presents the most urgent need for establishing robust assays in the hematological community. It represents the opportunity to study the function of HSCs isolated from patients with the diseases that we are trying to cure. While there are a number of studies that have used human:human transplantations in clinical settings to study the dynamics of HSCs,&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; the ability to characterize leukemic HSCs at a detailed molecular level and to treat them with experimental compounds to potentially modify those clonal dynamics for therapeutic purposes remains extremely limited. This is where the xenotransplantation assay comes to the fore, but defining an agreed set of standards in the field is a complex business, and a recent study in &lt;i&gt;HemaSphere&lt;/i&gt; by Mian et al. sheds some light on one of the key factors in transplantation biology—sex differences.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Sex differences in transplantation have been known about for some time, although the studies do not always agree on the how's and why's of these differences. Single HSC transplantation studies in mouse:mouse donor:recipient pairs showed that male HSCs did not perform well in female recipients, potentially due to a weak antigen coded for by the Y chromosome.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Another study,&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; in human:mouse xenotransplants, showed that female immunodeficient NOD/SCID/IL-2Rgc-null (NSG) mice were far superior as recipients of human cells with increases in both engraftment and proliferation of human HSCs (and this was also evidenced at the single-cell level). In this latter study, two potential reasons were speculated: first, that “female NSG mice might be more immunodeficient than males,” and second that “sex-associated factors, such as steroid hormones, can positively or negatively regulate human HSCs.” It is clear that sex matters, but with the emergence of new immunodeficient models and a general lack of comparative studies between male and female recipients, it is difficult to articulate a set of field recommendations for how to undertake xenotransplantation experiments with precious patient samples.&lt;/p&gt;&lt;p&gt;The recently published study by Mian et al.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; goes some way to addressing this. Using various immunodeficient mou","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 9","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.70000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142165674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human immunodeficiency virus-associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 人体免疫缺陷病毒相关淋巴瘤:EHA-ESMO 诊断、治疗和随访临床实践指南
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-09-03 DOI: 10.1002/hem3.150
Kai Hübel, Mark Bower, Igor Aurer, Mariana Bastos-Oreiro, Caroline Besson, Uta Brunnberg, Chiara Cattaneo, Simon Collins, Kate Cwynarski, Alessia D. Pria, Marcus Hentrich, Christian Hoffmann, Marie J. Kersten, Silvia Montoto, Jose-Tomas Navarro, Eric Oksenhendler, Alessandro Re, Josep-Maria Ribera, Philipp Schommers, Bastian von Tresckow, Christian Buske, Martin Dreyling, Andy Davies, the EHA and ESMO Guidelines Committees
<p>Non-Hodgkin lymphoma (NHL) remains the most common type of cancer and a leading cause of mortality in people who are living with human immunodeficiency virus (HIV).<span><sup>1</sup></span> This is despite a marked decrease in the incidence of HIV-associated NHL (HIV–NHL) following the introduction of combination antiretroviral therapy (ART) in the mid-1990s.<span><sup>2</sup></span> In contrast, the incidence of Hodgkin lymphoma (HL) increased slightly but has remained stable since 2000.<span><sup>1</sup></span> Compared with the age- and gender-matched general population, the incidences of HIV–NHL and HIV-associated HL (HIV–HL) are increased ~10- to 20-fold.<span><sup>3</sup></span></p><p>The most common histological types of HIV-associated lymphomas are diffuse large B-cell lymphoma (DLBCL; 37%), HL (26%) and Burkitt lymphoma (BL; 20%).<span><sup>4</sup></span> Independent risk factors for DLBCL in people living with HIV (PLWH) include a low cluster of differentiation (CD)4 T-cell count and an uncontrolled HIV-1 viral load (VL).<span><sup>5</sup></span> The availability of ART and better management of opportunistic infections allow PLWH to receive the same treatments as people without HIV, including intensive therapies, such as autologous stem-cell transplantation (ASCT), allogeneic stem-cell transplantation (allo-SCT) and chimeric antigen receptor T-cell (CAR-T) therapy. Patients with HIV-associated lymphomas should be enrolled in clinical trials whenever possible.</p><p>The aim of this guideline is to provide practical clinical guidance and recommendations to clinicians who manage HIV-associated lymphomas.</p><p>Diagnostic procedures in patients with HIV-associated lymphoma generally mirror those recommended for lymphoma in the general population and those necessary to assess the severity and complications of HIV and its treatment (see Supporting Information S1: Table S1).</p><p>Lymphoma should be diagnosed via tumour biopsy, preferably excisional, that is evaluated by an expert haematopathologist using immunohistochemistry (IHC) and molecular techniques. In exceptional cases when no tumour mass can be biopsied, diagnosis can be made by cytology and flow cytometry.</p><p>Lymphoma staging should involve a contrast-enhanced computed tomography (CT) scan of the neck, chest, abdomen and pelvis and a bone marrow biopsy. A staging [<sup>18</sup>F]2-fluoro-2-deoxy-<span>d</span>-glucose (FDG)–positron emission tomography (PET)–CT scan is more sensitive, especially for extranodal disease. FDG–PET–CT may, however, have a higher false-positive rate in PLWH due to immune deficiency-related lymphoid hyperplasia and non-suppressed HIV infection.<span><sup>6</sup></span> Interim FDG–PET–CT (iFDG–PET–CT) results should, therefore, be interpreted cautiously if used to escalate treatment and when analysing end-of-treatment response; if there is doubt, FDG-avid lesions should be re-biopsied. Otherwise, response criteria do not differ from those used in imm
非霍奇金淋巴瘤(NHL)仍然是人类免疫缺陷病毒(HIV)感染者最常见的癌症类型和主要死因。1 尽管在 20 世纪 90 年代中期引入抗逆转录病毒联合疗法(ART)后,HIV 相关 NHL(HIV-NHL)的发病率明显下降。相比之下,霍奇金淋巴瘤(HL)的发病率略有上升,但自 2000 年以来一直保持稳定。1 与年龄和性别匹配的普通人群相比,HIV-NHL 和 HIV 相关 HL(HIV-HL)的发病率增加了约 10-20 倍。4 HIV 感染者(PLWH)中 DLBCL 的独立风险因素包括低分化群(CD)4 T 细胞计数和未控制的 HIV-1 病毒载量(VL)。5 抗逆转录病毒疗法的可用性和对机会性感染的更好管理,使艾滋病病毒感染者能够接受与非艾滋病病毒感染者相同的治疗,包括强化治疗,如自体干细胞移植(ASCT)、异体干细胞移植(allo-SCT)和嵌合抗原受体T细胞(CAR-T)疗法。本指南旨在为治疗艾滋病相关淋巴瘤的临床医生提供实用的临床指导和建议。HIV相关淋巴瘤患者的诊断程序一般参照普通人群淋巴瘤的诊断程序,以及评估HIV及其治疗的严重程度和并发症所需的诊断程序(见佐证资料S1:表S1)。淋巴瘤应通过肿瘤活检进行诊断,最好是切除活检,由血液病理专家使用免疫组化(IHC)和分子技术进行评估。淋巴瘤分期应包括颈部、胸部、腹部和盆腔的对比增强计算机断层扫描(CT)和骨髓活检。分期[18F]2-氟-2-脱氧-d-葡萄糖(FDG)-正电子发射断层扫描(PET)-CT扫描更为敏感,尤其是对结节外疾病。然而,由于免疫缺陷相关淋巴细胞增生和未抑制的 HIV 感染,FDG-PET-CT 在 PLWH 中的假阳性率可能较高。6 因此,如果将中期 FDG-PET-CT (iFDG-PET-CT)结果用于升级治疗和分析治疗末期反应时,应谨慎解释;如果存在疑问,应重新对 FDG-avid 病变进行活检。磁共振成像(MRI)是对中枢神经系统(CNS)淋巴瘤进行分期和反应评估的最佳方法。磁共振成像(MRI)是对中枢神经系统(CNS)淋巴瘤进行分期和反应评估的最佳方法。然而,脑机会性感染可能会模仿 PLWH 淋巴瘤。小型病例系列表明,FDG-PET-CT 可以区分脑部感染(如弓形虫病)7 和中枢神经系统淋巴瘤,但活检(最好是立体定向)仍是诊断的金标准。新诊断出的 HIV 患者的所有其他检查都应遵循每年更新的、循证分级的欧洲获得性免疫缺陷综合征临床协会指南,可在 http://www.eacsociety.org/guidelines/eacs-guidelines/.The 上查阅。HIV 感染者患 HL 的主要风险因素是 CD4 细胞计数中度降低。在最近的一项研究中,CD4 细胞数为 100-200 cells/µL 的患者与参照组(CD4 细胞数为 500 cells/µL)相比,HL 的危险比最高(6.36)。5 相反,与 VL ≤50 copies/mL 相比,HIV-1 VL 较高(50 copies/mL)与 HL 风险增加无关。发病率与 CD4 细胞数或 HIV 血浆病毒血症无相关性。本临床实践指南 (CPG) 是根据 ESMO CPG 制定标准操作程序 (https://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology) 制定的。相关文献由专家作者选定。新疗法/适应症的 FDA/EMA 或其他监管机构的批准情况已在编写本 CPG 时报告。证据等级和推荐等级的应用系统见佐证资料 S1:表 S4。作者认为没有分级的声明是合理的标准临床实践。本指南使用 "以人为本 "的术语。有关本 CPG 的未来更新,包括 eUpdates 和 Living Guidelines,请访问 ESMO Guidelines 网站:https://www.esmo.org/guidelines/guidelines-by-topic/haematological-malignancies.All 作者构思、撰写并批准了最终版本。
{"title":"Human immunodeficiency virus-associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","authors":"Kai Hübel,&nbsp;Mark Bower,&nbsp;Igor Aurer,&nbsp;Mariana Bastos-Oreiro,&nbsp;Caroline Besson,&nbsp;Uta Brunnberg,&nbsp;Chiara Cattaneo,&nbsp;Simon Collins,&nbsp;Kate Cwynarski,&nbsp;Alessia D. Pria,&nbsp;Marcus Hentrich,&nbsp;Christian Hoffmann,&nbsp;Marie J. Kersten,&nbsp;Silvia Montoto,&nbsp;Jose-Tomas Navarro,&nbsp;Eric Oksenhendler,&nbsp;Alessandro Re,&nbsp;Josep-Maria Ribera,&nbsp;Philipp Schommers,&nbsp;Bastian von Tresckow,&nbsp;Christian Buske,&nbsp;Martin Dreyling,&nbsp;Andy Davies,&nbsp;the EHA and ESMO Guidelines Committees","doi":"10.1002/hem3.150","DOIUrl":"https://doi.org/10.1002/hem3.150","url":null,"abstract":"&lt;p&gt;Non-Hodgkin lymphoma (NHL) remains the most common type of cancer and a leading cause of mortality in people who are living with human immunodeficiency virus (HIV).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; This is despite a marked decrease in the incidence of HIV-associated NHL (HIV–NHL) following the introduction of combination antiretroviral therapy (ART) in the mid-1990s.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; In contrast, the incidence of Hodgkin lymphoma (HL) increased slightly but has remained stable since 2000.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Compared with the age- and gender-matched general population, the incidences of HIV–NHL and HIV-associated HL (HIV–HL) are increased ~10- to 20-fold.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The most common histological types of HIV-associated lymphomas are diffuse large B-cell lymphoma (DLBCL; 37%), HL (26%) and Burkitt lymphoma (BL; 20%).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Independent risk factors for DLBCL in people living with HIV (PLWH) include a low cluster of differentiation (CD)4 T-cell count and an uncontrolled HIV-1 viral load (VL).&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; The availability of ART and better management of opportunistic infections allow PLWH to receive the same treatments as people without HIV, including intensive therapies, such as autologous stem-cell transplantation (ASCT), allogeneic stem-cell transplantation (allo-SCT) and chimeric antigen receptor T-cell (CAR-T) therapy. Patients with HIV-associated lymphomas should be enrolled in clinical trials whenever possible.&lt;/p&gt;&lt;p&gt;The aim of this guideline is to provide practical clinical guidance and recommendations to clinicians who manage HIV-associated lymphomas.&lt;/p&gt;&lt;p&gt;Diagnostic procedures in patients with HIV-associated lymphoma generally mirror those recommended for lymphoma in the general population and those necessary to assess the severity and complications of HIV and its treatment (see Supporting Information S1: Table S1).&lt;/p&gt;&lt;p&gt;Lymphoma should be diagnosed via tumour biopsy, preferably excisional, that is evaluated by an expert haematopathologist using immunohistochemistry (IHC) and molecular techniques. In exceptional cases when no tumour mass can be biopsied, diagnosis can be made by cytology and flow cytometry.&lt;/p&gt;&lt;p&gt;Lymphoma staging should involve a contrast-enhanced computed tomography (CT) scan of the neck, chest, abdomen and pelvis and a bone marrow biopsy. A staging [&lt;sup&gt;18&lt;/sup&gt;F]2-fluoro-2-deoxy-&lt;span&gt;d&lt;/span&gt;-glucose (FDG)–positron emission tomography (PET)–CT scan is more sensitive, especially for extranodal disease. FDG–PET–CT may, however, have a higher false-positive rate in PLWH due to immune deficiency-related lymphoid hyperplasia and non-suppressed HIV infection.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Interim FDG–PET–CT (iFDG–PET–CT) results should, therefore, be interpreted cautiously if used to escalate treatment and when analysing end-of-treatment response; if there is doubt, FDG-avid lesions should be re-biopsied. Otherwise, response criteria do not differ from those used in imm","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 9","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.150","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142130443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes 对小儿霍奇金淋巴瘤进行单细胞 RNA 测序,研究对 T 细胞亚型的抑制作用。
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-09-02 DOI: 10.1002/hem3.149
Jurrian K. de Kanter, Alexander S. Steemers, Daniel Montiel Gonzalez, Ravian L. van Ineveld, Catharina Blijleven, Niels Groenen, Laurianne Trabut, Marijn A. Scheijde-Vermeulen, Liset Westera, Auke Beishuizen, Anne C. Rios, Frank C. P. Holstege, Arianne M. Brandsma, Thanasis Margaritis, Ruben van Boxtel, Friederike Meyer-Wentrup

Pediatric classic Hodgkin lymphoma (cHL) patients have a high survival rate but suffer from severe long-term side effects induced by chemo- and radiotherapy. cHL tumors are characterized by the low fraction (0.1%–10%) of malignant Hodgkin and Reed–Sternberg (HRS) cells in the tumor. The HRS cells depend on the surrounding immune cells for survival and growth. This dependence is leveraged by current treatments that target the PD-1/PD-L1 axis in cHL tumors. The development of more targeted therapies that are specific for the tumor and are therefore less toxic for healthy tissue compared with conventional chemotherapy could improve the quality of life of pediatric cHL survivors. Here, we applied single-cell RNA sequencing (scRNA-seq) on isolated HRS cells and the immune cells from the same cHL tumors. Besides TNFRSF8 (CD30), we identified other genes of cell surface proteins that are consistently overexpressed in HRS cells, such as NRXN3 and LRP8, which can potentially be used as alternative targets for antibody–drug conjugates or CAR T cells. Finally, we identified potential interactions by which HRS cells inhibit T cells, among which are the galectin-1/CD69 and HLA-II/LAG3 interactions. RNAscope was used to validate the enrichment of CD69 and LAG3 expression on T cells near HRS cells and indicated large variability of the interaction strength with the corresponding ligands between patients and between tumor tissue regions. In conclusion, this study identifies new potential therapeutic targets for cHL and highlights the importance of studying heterogeneity when identifying therapy targets, specifically those that target tumor-immune cell interactions.

小儿典型霍奇金淋巴瘤(cHL)患者的存活率很高,但长期遭受化疗和放疗引起的严重副作用。cHL肿瘤的特点是肿瘤中恶性霍奇金和里德-斯登堡(HRS)细胞的比例较低(0.1%-10%)。HRS细胞的生存和生长依赖于周围的免疫细胞。目前针对 cHL 肿瘤中 PD-1/PD-L1 轴的治疗利用了这种依赖性。与传统化疗相比,针对肿瘤开发更具特异性、对健康组织毒性更小的靶向疗法可改善小儿 cHL 幸存者的生活质量。在这里,我们应用单细胞RNA测序(scRNA-seq)对分离出的HRS细胞和来自同一cHL肿瘤的免疫细胞进行了研究。除了TNFRSF8(CD30)外,我们还发现了其他在HRS细胞中持续过表达的细胞表面蛋白基因,如NRXN3和LRP8,它们有可能被用作抗体药物共轭物或CAR T细胞的替代靶点。最后,我们确定了HRS细胞抑制T细胞的潜在相互作用,其中包括galectin-1/CD69和HLA-II/LAG3相互作用。我们使用 RNAscope 验证了 HRS 细胞附近 T 细胞上 CD69 和 LAG3 的富集表达,结果显示,不同患者和不同肿瘤组织区域与相应配体的相互作用强度存在很大差异。总之,这项研究为 cHL 确定了新的潜在治疗靶点,并强调了在确定治疗靶点时研究异质性的重要性,特别是那些针对肿瘤-免疫细胞相互作用的靶点。
{"title":"Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes","authors":"Jurrian K. de Kanter,&nbsp;Alexander S. Steemers,&nbsp;Daniel Montiel Gonzalez,&nbsp;Ravian L. van Ineveld,&nbsp;Catharina Blijleven,&nbsp;Niels Groenen,&nbsp;Laurianne Trabut,&nbsp;Marijn A. Scheijde-Vermeulen,&nbsp;Liset Westera,&nbsp;Auke Beishuizen,&nbsp;Anne C. Rios,&nbsp;Frank C. P. Holstege,&nbsp;Arianne M. Brandsma,&nbsp;Thanasis Margaritis,&nbsp;Ruben van Boxtel,&nbsp;Friederike Meyer-Wentrup","doi":"10.1002/hem3.149","DOIUrl":"10.1002/hem3.149","url":null,"abstract":"<p>Pediatric classic Hodgkin lymphoma (cHL) patients have a high survival rate but suffer from severe long-term side effects induced by chemo- and radiotherapy. cHL tumors are characterized by the low fraction (0.1%–10%) of malignant Hodgkin and Reed–Sternberg (HRS) cells in the tumor. The HRS cells depend on the surrounding immune cells for survival and growth. This dependence is leveraged by current treatments that target the PD-1/PD-L1 axis in cHL tumors. The development of more targeted therapies that are specific for the tumor and are therefore less toxic for healthy tissue compared with conventional chemotherapy could improve the quality of life of pediatric cHL survivors. Here, we applied single-cell RNA sequencing (scRNA-seq) on isolated HRS cells and the immune cells from the same cHL tumors. Besides <i>TNFRSF8</i> (CD30), we identified other genes of cell surface proteins that are consistently overexpressed in HRS cells, such as <i>NRXN3</i> and <i>LRP8</i>, which can potentially be used as alternative targets for antibody–drug conjugates or CAR T cells. Finally, we identified potential interactions by which HRS cells inhibit T cells, among which are the galectin-1/CD69 and HLA-II/LAG3 interactions. RNAscope was used to validate the enrichment of CD69 and LAG3 expression on T cells near HRS cells and indicated large variability of the interaction strength with the corresponding ligands between patients and between tumor tissue regions. In conclusion, this study identifies new potential therapeutic targets for cHL and highlights the importance of studying heterogeneity when identifying therapy targets, specifically those that target tumor-immune cell interactions.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 9","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11369206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab 复发/难治性慢性淋巴细胞白血病患者接受 Venetoclax 加利妥昔单抗治疗后的长期免疫变化
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-27 DOI: 10.1002/hem3.146
Arnon P. Kater, Barbara F. Eichhorst, Carolyn J. Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani-Mulero, Michelle Boyer, John F. Seymour

Immune dysregulation is a hallmark of chronic lymphocytic leukemia (CLL). Anti-CD20 antibodies (e.g., rituximab [R]) can be combined with venetoclax (Ven) to treat CLL. However, anti-CD20 antibodies can increase hypogammaglobulinemia risk, while the effects of Ven on immune dysregulation are still uncertain. We report long-term immune changes in VenR- and bendamustine-R (BR)-treated patients with relapsed/refractory CLL in the MURANO trial (NCT02005471). Patients were randomized to fixed-duration VenR (2 years Ven; VenR for the first 6 months) or BR (6 months). Immune cell levels were evaluated at the end of combination treatment (EOCT), end of treatment (EOT; VenR arm only), and 12 and 24 months post-EOCT. Overall, 130/194 VenR- and 134/195 BR-treated patients completed treatment without progressive disease. In patients who completed VenR combination therapy, median immunoglobulin (Ig)G and IgM levels decreased from baseline to EOT (p ≤ 0.01 and p ≤ 0.0001, respectively); by 24 months, post-EOT IgG had returned to baseline level and IgM had increased from baseline (p ≤ 0.001). Median IgA levels increased from baseline to 12 (p ≤ 0.0001) and 24 months post-EOT (p ≤ 0.0001). In BR-treated patients, changes in IgG, IgA, and IgM levels across the assessed time points were not significant, and by 24 months, post-EOCT IgG, IgA, and IgM were above baseline levels. Grade ≥3 infection rates on treatment were low. Overall, immune recovery was observed with VenR and BR, with stabilization of Ig levels after treatment. Post-treatment infection rates were generally low, making these very tolerable therapies for CLL.

免疫失调是慢性淋巴细胞白血病(CLL)的标志。抗 CD20 抗体(如利妥昔单抗 [R])可与 Venetoclax(Ven)联合治疗 CLL。然而,抗CD20抗体会增加低丙种球蛋白血症的风险,而Ven对免疫失调的影响仍不确定。我们报告了MURANO试验(NCT02005471)中接受VenR和苯达莫司汀-R(BR)治疗的复发/难治性CLL患者的长期免疫变化。患者随机接受固定疗程的 VenR(2 年 Ven;前 6 个月 VenR)或 BR(6 个月)治疗。在联合治疗结束(EOCT)、治疗结束(EOT;仅VenR组)以及EOCT后12个月和24个月对免疫细胞水平进行评估。总体而言,130/194 名 VenR 治疗患者和 134/195 名 BR 治疗患者在完成治疗后未出现疾病进展。在完成VenR联合治疗的患者中,免疫球蛋白(Ig)G和IgM的中位水平从基线到EOT均有所下降(分别为p≤0.01和p≤0.0001);到24个月时,EOT后IgG已恢复到基线水平,IgM则从基线上升(p≤0.001)。中位 IgA 水平从基线上升至 EOT 后 12 个月(p ≤ 0.0001)和 24 个月(p ≤ 0.0001)。在接受BR治疗的患者中,IgG、IgA和IgM水平在各评估时间点的变化并不显著,到24个月时,EOCT后的IgG、IgA和IgM均高于基线水平。治疗期间≥3级感染率较低。总体而言,VenR和BR可观察到免疫恢复,治疗后Ig水平趋于稳定。治疗后的感染率普遍较低,因此这些疗法在治疗CLL时非常容易耐受。
{"title":"Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab","authors":"Arnon P. Kater,&nbsp;Barbara F. Eichhorst,&nbsp;Carolyn J. Owen,&nbsp;Ulrich Jaeger,&nbsp;Brenda Chyla,&nbsp;Marcus Lefebure,&nbsp;Rosemary Millen,&nbsp;Yanwen Jiang,&nbsp;Maria Thadani-Mulero,&nbsp;Michelle Boyer,&nbsp;John F. Seymour","doi":"10.1002/hem3.146","DOIUrl":"https://doi.org/10.1002/hem3.146","url":null,"abstract":"<p>Immune dysregulation is a hallmark of chronic lymphocytic leukemia (CLL). Anti-CD20 antibodies (e.g., rituximab [R]) can be combined with venetoclax (Ven) to treat CLL. However, anti-CD20 antibodies can increase hypogammaglobulinemia risk, while the effects of Ven on immune dysregulation are still uncertain. We report long-term immune changes in VenR- and bendamustine-R (BR)-treated patients with relapsed/refractory CLL in the MURANO trial (NCT02005471). Patients were randomized to fixed-duration VenR (2 years Ven; VenR for the first 6 months) or BR (6 months). Immune cell levels were evaluated at the end of combination treatment (EOCT), end of treatment (EOT; VenR arm only), and 12 and 24 months post-EOCT. Overall, 130/194 VenR- and 134/195 BR-treated patients completed treatment without progressive disease. In patients who completed VenR combination therapy, median immunoglobulin (Ig)G and IgM levels decreased from baseline to EOT (<i>p</i> ≤ 0.01 and <i>p</i> ≤ 0.0001, respectively); by 24 months, post-EOT IgG had returned to baseline level and IgM had increased from baseline (<i>p</i> ≤ 0.001). Median IgA levels increased from baseline to 12 (<i>p</i> ≤ 0.0001) and 24 months post-EOT (<i>p</i> ≤ 0.0001). In BR-treated patients, changes in IgG, IgA, and IgM levels across the assessed time points were not significant, and by 24 months, post-EOCT IgG, IgA, and IgM were above baseline levels. Grade ≥3 infection rates on treatment were low. Overall, immune recovery was observed with VenR and BR, with stabilization of Ig levels after treatment. Post-treatment infection rates were generally low, making these very tolerable therapies for CLL.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 8","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hem3.146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142077919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA binding protein-directed control of leukemic stem cell evolution and function RNA 结合蛋白对白血病干细胞进化和功能的定向控制
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-22 DOI: 10.1002/hem3.116
Pratik Joshi, Ava Keyvani Chahi, Lina Liu, Steven Moreira, Ana Vujovic, Kristin J. Hope

Strict control over hematopoietic stem cell decision making is essential for healthy life-long blood production and underpins the origins of hematopoietic diseases. Acute myeloid leukemia (AML) in particular is a devastating hematopoietic malignancy that arises from the clonal evolution of disease-initiating primitive cells which acquire compounding genetic changes over time and culminate in the generation of leukemic stem cells (LSCs). Understanding the molecular underpinnings of these driver cells throughout their development will be instrumental in the interception of leukemia, the enabling of effective treatment of pre-leukemic conditions, as well as the development of strategies to target frank AML disease. To this point, a number of precancerous myeloid disorders and age-related alterations are proving as instructive models to gain insights into the initiation of LSCs. Here, we explore this myeloid dysregulation at the level of post–transcriptional control, where RNA-binding proteins (RBPs) function as core effectors. Through regulating the interplay of a myriad of RNA metabolic processes, RBPs orchestrate transcript fates to govern gene expression in health and disease. We describe the expanding appreciation of the role of RBPs and their post–transcriptional networks in sustaining healthy hematopoiesis and their dysregulation in the pathogenesis of clonal myeloid disorders and AML, with a particular emphasis on findings described in human stem cells. Lastly, we discuss key breakthroughs that highlight RBPs and post–transcriptional control as actionable targets for precision therapy of AML.

对造血干细胞决策的严格控制是终身健康造血的关键,也是造血疾病的根源。急性髓性白血病(AML)是一种毁灭性的造血恶性肿瘤,它是由致病原始细胞的克隆进化引起的,随着时间的推移,原始细胞的基因会发生复合变化,最终产生白血病干细胞(LSC)。了解这些驱动细胞在整个发育过程中的分子基础,将有助于阻断白血病、有效治疗白血病前期病症以及开发针对急性髓细胞白血病的策略。在这一点上,一些癌前髓细胞疾病和与年龄相关的改变被证明是具有启发性的模型,可用于深入了解 LSCs 的启动。在这里,我们从转录后控制的层面探讨了这种髓系失调,RNA 结合蛋白(RBPs)在其中发挥着核心效应物的作用。通过调节无数 RNA 代谢过程的相互作用,RBPs 可协调转录本的命运,从而控制健康和疾病中的基因表达。我们描述了人们对 RBPs 及其转录后网络在维持健康造血过程中的作用以及它们在克隆性髓系疾病和急性髓细胞性白血病发病机制中的失调的认识不断扩大,并特别强调了在人类干细胞中的发现。最后,我们将讨论一些关键性突破,这些突破强调了RBPs和转录后控制是急性髓细胞性白血病精准治疗的可行靶点。
{"title":"RNA binding protein-directed control of leukemic stem cell evolution and function","authors":"Pratik Joshi,&nbsp;Ava Keyvani Chahi,&nbsp;Lina Liu,&nbsp;Steven Moreira,&nbsp;Ana Vujovic,&nbsp;Kristin J. Hope","doi":"10.1002/hem3.116","DOIUrl":"10.1002/hem3.116","url":null,"abstract":"<p>Strict control over hematopoietic stem cell decision making is essential for healthy life-long blood production and underpins the origins of hematopoietic diseases. Acute myeloid leukemia (AML) in particular is a devastating hematopoietic malignancy that arises from the clonal evolution of disease-initiating primitive cells which acquire compounding genetic changes over time and culminate in the generation of leukemic stem cells (LSCs). Understanding the molecular underpinnings of these driver cells throughout their development will be instrumental in the interception of leukemia, the enabling of effective treatment of pre-leukemic conditions, as well as the development of strategies to target frank AML disease. To this point, a number of precancerous myeloid disorders and age-related alterations are proving as instructive models to gain insights into the initiation of LSCs. Here, we explore this myeloid dysregulation at the level of post–transcriptional control, where RNA-binding proteins (RBPs) function as core effectors. Through regulating the interplay of a myriad of RNA metabolic processes, RBPs orchestrate transcript fates to govern gene expression in health and disease. We describe the expanding appreciation of the role of RBPs and their post–transcriptional networks in sustaining healthy hematopoiesis and their dysregulation in the pathogenesis of clonal myeloid disorders and AML, with a particular emphasis on findings described in human stem cells. Lastly, we discuss key breakthroughs that highlight RBPs and post–transcriptional control as actionable targets for precision therapy of AML.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 8","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma 接受 CD19 CAR-T 治疗的大 B 细胞淋巴瘤患者预后的生物标志物。
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-22 DOI: 10.1002/hem3.130
Inna Y. Gong, Daisy Tran, Samuel Saibil, Rob C. Laister, John Kuruvilla

CD19-directed autologous chimeric antigen receptor T cell (CAR-T) therapy has transformed the management of relapsed/refractory (R/R) large B cell lymphoma (LBCL). Initially approved in the third line and beyond setting, CAR-T is now standard of care (SOC) for second-line treatment in patients with refractory disease or early relapse (progression within 12 months) following primary chemoimmunotherapy. Despite becoming SOC, most patients do not achieve complete response, and long-term cure is only observed in approximately 40% of patients. Accordingly, there is an urgent need to better understand the mechanisms of treatment failure and to identify patients that are unlikely to benefit from SOC CAR-T. The field needs robust biomarkers to predict treatment outcome, as better understanding of prognostic factors and mechanisms of resistance can inform on the design of novel treatment approaches for patients predicted to respond poorly to SOC CAR-T. This review aims to provide a comprehensive overview of clinical, molecular, imaging, and cellular features that have been shown to influence outcomes of CAR-T therapy in patients with R/R LBCL.

CD19 引导的自体嵌合抗原受体 T 细胞(CAR-T)疗法改变了对复发/难治性(R/R)大 B 细胞淋巴瘤(LBCL)的治疗。CAR-T 最初被批准用于三线及三线以上治疗,现在已成为二线治疗的标准疗法(SOC),用于初治化疗免疫疗法后难治性疾病或早期复发(12 个月内病情进展)患者的治疗。尽管已成为 SOC,但大多数患者并未获得完全应答,只有约 40% 的患者可观察到长期治愈。因此,亟需更好地了解治疗失败的机制,并识别不太可能从 SOC CAR-T 中获益的患者。该领域需要强有力的生物标志物来预测治疗结果,因为更好地了解预后因素和耐药机制可以为设计新型治疗方法提供信息,这些方法适用于预计对 SOC CAR-T 反应不佳的患者。本综述旨在全面概述已被证明会影响R/R LBCL患者CAR-T疗法疗效的临床、分子、影像和细胞特征。
{"title":"Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma","authors":"Inna Y. Gong,&nbsp;Daisy Tran,&nbsp;Samuel Saibil,&nbsp;Rob C. Laister,&nbsp;John Kuruvilla","doi":"10.1002/hem3.130","DOIUrl":"10.1002/hem3.130","url":null,"abstract":"<p>CD19-directed autologous chimeric antigen receptor T cell (CAR-T) therapy has transformed the management of relapsed/refractory (R/R) large B cell lymphoma (LBCL). Initially approved in the third line and beyond setting, CAR-T is now standard of care (SOC) for second-line treatment in patients with refractory disease or early relapse (progression within 12 months) following primary chemoimmunotherapy. Despite becoming SOC, most patients do not achieve complete response, and long-term cure is only observed in approximately 40% of patients. Accordingly, there is an urgent need to better understand the mechanisms of treatment failure and to identify patients that are unlikely to benefit from SOC CAR-T. The field needs robust biomarkers to predict treatment outcome, as better understanding of prognostic factors and mechanisms of resistance can inform on the design of novel treatment approaches for patients predicted to respond poorly to SOC CAR-T. This review aims to provide a comprehensive overview of clinical, molecular, imaging, and cellular features that have been shown to influence outcomes of CAR-T therapy in patients with R/R LBCL.</p>","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 8","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA 在CEBPA突变的急性髓细胞性白血病中分子可测量残留病检测的预后相关性。
IF 7.6 2区 医学 Q1 HEMATOLOGY Pub Date : 2024-08-15 DOI: 10.1002/hem3.141
Christian M. Vonk, Emma L. Boertjes, Francois G. Kavelaars, Melissa Rijken, Jolinda M. L. Konijnenburg, Roxanne E. Cromwell, Bob Löwenberg, Tim Grob, Peter J. M. Valk
<p>Mutations in the CCAAT/enhancer binding protein alpha (<i>CEBPA</i>) are found in 2%–15% (mean 5%) of <i>de novo</i> acute myeloid leukemia (AML) patients.<span><sup>1</sup></span> <i>CEBPA</i> encodes a transcription factor that is important for hematopoietic stem cell (HSC) self-renewal as well as myeloid differentiation of hematopoietic progenitors.<span><sup>2</sup></span> The characteristic mutations in the CEBPA protein involve frame-shift mutations in the N-terminal transactivation domains and in-frame mutations in the C-terminal basic leucine zipper (bZIP).<span><sup>2</sup></span> Recently, the in-frame <i>CEBPA</i> bZIP mutations were incorporated in the 2022 European LeukemiaNet (ELN) risk classification as a favorable risk factor,<span><sup>3</sup></span> replacing the <i>CEBPA</i> double mutations (<i>CEBPA</i><sup>dm</sup>) as favorable marker in the preceding ELN2017 guidelines.<span><sup>4</sup></span></p><p>Recent advances in molecular minimal residual disease (MRD) detection in complete remission (CR) have shown profound prognostic value of a selection of AML-specific gene mutations.<span><sup>5-7</sup></span> However, the prognostic impact of persisting <i>CEBPA</i> mutations in CR has not been thoroughly investigated in AML patients. Here, we explored the prognostic impact of mutant <i>CEBPA</i> MRD in a relatively large cohort of 84 AML patients with mutated <i>CEBPA</i> by deep next-generation sequencing (NGS).</p><p>AML patients enrolled in the Dutch-Belgian Cooperative Trial Group for Hematology-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) clinical trials HO42A, HO92, HO102, HO103, and HO132 were included. All trial participants provided written informed consent in accordance with the Declaration of Helsinki, and were treated according to their respective treatment protocol (www.hovon.nl). Patients were assessed for gene mutations on diagnostic bone marrow samples using the TruSight Myeloid Sequencing panel (Illumina) targeting 54 frequently mutated genes in AML.<span><sup>8</sup></span> Since NGS quality and depth of sequencing of the <i>CEBPA</i> gene varies when using this gene panel, <i>CEBPA</i> targeted sequencing was additionally performed on DNA of these diagnostic samples using a custom four-amplicon polymerase chain reaction (PCR) approach (amplicons A, B, C1, C2; Supporting Information: Methods).<span><sup>9</sup></span> A total of 144 <i>CEBPA</i> mutant patients out of 1913 AML cases was identified, of which 84 with available CR samples were included for mutant <i>CEBPA</i> MRD assessment. Targeted deep sequencing was performed on 100 ng of DNA obtained at CR, after two cycles of standard induction chemotherapy and pretransplant, using the four-amplicon PCR-based NGS approach.<span><sup>8, 9</sup></span></p><p>At diagnosis, 43 out of 84 cases harbored a mutation in the bZIP region (bzip), whereas 41 carried other mutations (non-bzip) (Supporting Information S1: Table 1). All <i>CEBPA
在2%-15%(平均5%)的新发急性髓性白血病(AML)患者中发现了CCAAT/增强子结合蛋白α(CEBPA)的突变。1 CEBPA编码的转录因子对造血干细胞(HSC)的自我更新以及造血祖细胞的髓样分化非常重要。2 最近,CEBPA bZIP 框架内突变被纳入 2022 年欧洲白血病网络(ELN)风险分类,作为一个有利的风险因素,3 取代 CEBPA 双突变(CEBPAdm)成为之前 ELN2017 指南中的有利标记。完全缓解(CR)中最小残留病(MRD)分子检测的最新进展显示,部分 AML 特异性基因突变具有深远的预后价值。在此,我们通过深度下一代测序(NGS),在一个相对较大的 84 例突变 CEBPA 的 AML 患者队列中探讨了突变 CEBPA MRD 对预后的影响。AML 患者参加了荷兰-比利时血液肿瘤学合作试验组(HOVON)和瑞士临床癌症研究组(SAKK)的临床试验 HO42A、HO92、HO102、HO103 和 HO132。所有试验参与者均根据《赫尔辛基宣言》提交了知情同意书,并按照各自的治疗方案(www.hovon.nl)接受治疗。使用针对急性髓细胞性白血病中 54 个常见突变基因的 TruSight 骨髓测序面板(Illumina)对患者的诊断性骨髓样本进行基因突变评估8。9 在 1913 例 AML 中,共发现了 144 例 CEBPA 突变患者,其中 84 例有 CR 样本,用于突变 CEBPA MRD 评估。在诊断时,84 例患者中有 43 例携带 bZIP 区突变(bzip),41 例携带其他突变(非 bzip)(佐证信息 S1:表 1)。所有 CEBPAbzip 突变均为框内插入。CEBPAbzip患者明显更年轻,但在诊断、巩固治疗或治疗方案时,CEBPAbzip与CEBPAnon-bzip患者在性别、出血量和白细胞计数方面无明显差异(佐证资料S1:表2)。突变随后根据 ELN2017(单突变:CEBPAsm [n = 28] vs. 双突变:CEBPAdm [n = 56])和 ELN2022(CEBPAbzip [n = 43] 和 CEBPAnon-bzip [n = 41])风险分层进行分类(佐证资料 S1:图 1)。在 ELN2022 中,所有 CEBPAbzip 患者仍属于有利风险组,而根据 ELN2022 标准,CEBPAnon-bzip AML 患者被分为有利(27%)、中间(39%)或不利(34%)风险组。与ELN2017相比,84例CEBPA突变AML患者中有17例被重新分层为不同的ELN2022风险类别,即15例CEBPAdm AML患者(27%)不携带有利的框架内bZIP突变,而2例CEBPAsm AML患者携带有利的框架内bZIP突变(佐证资料S1:图1)。在完整的 CEBPA 突变 AML 队列中,TET2 最常发生突变(24%),其次是 GATA2(23%)、NPM1(17%)、NRAS(17%)和 DNMT3A(16%)(佐证资料 S1:图 2)。6例CEBPA突变型AML患者没有任何已知的共突变。NPM1(32%,p &lt; 0.001)、DNMT3A(27%,p = 0.006)、SRSF2(20%,p = 0.014)、RUNX1(17%,p = 0.028)、IDH2(17%,p = 0.005)、ASXL1(15%,p = 0.011)、FLT3-TKD(15%,p = 0.011)和 IDH1(12%,p = 0.024)在CEBPAnon-bzip患者中突变的频率明显更高,而GATA2(40%,p &lt; 0.001)和WT1(23%,p = 0.026)在CEBPAbzip患者中突变的频率更高(佐证资料S1:图2)。接下来,我们研究了不同CEBPA突变AML亚组之间临床结局的差异。我们使用 Kaplan-Meier 估计值比较了各亚组之间的总生存期(OS)和累积复发率(CIR),对象为诊断时存在突变 CEBPA 的所有 AML 患者(n = 84)。OS和CIR的计算时间为CR取样日期至事件发生日期。不出所料,与CEBPA非突变相比,诊断时存在CEBPAbzip突变与OS改善相关(p = 0.05)。
{"title":"Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA","authors":"Christian M. Vonk,&nbsp;Emma L. Boertjes,&nbsp;Francois G. Kavelaars,&nbsp;Melissa Rijken,&nbsp;Jolinda M. L. Konijnenburg,&nbsp;Roxanne E. Cromwell,&nbsp;Bob Löwenberg,&nbsp;Tim Grob,&nbsp;Peter J. M. Valk","doi":"10.1002/hem3.141","DOIUrl":"10.1002/hem3.141","url":null,"abstract":"&lt;p&gt;Mutations in the CCAAT/enhancer binding protein alpha (&lt;i&gt;CEBPA&lt;/i&gt;) are found in 2%–15% (mean 5%) of &lt;i&gt;de novo&lt;/i&gt; acute myeloid leukemia (AML) patients.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; &lt;i&gt;CEBPA&lt;/i&gt; encodes a transcription factor that is important for hematopoietic stem cell (HSC) self-renewal as well as myeloid differentiation of hematopoietic progenitors.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The characteristic mutations in the CEBPA protein involve frame-shift mutations in the N-terminal transactivation domains and in-frame mutations in the C-terminal basic leucine zipper (bZIP).&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Recently, the in-frame &lt;i&gt;CEBPA&lt;/i&gt; bZIP mutations were incorporated in the 2022 European LeukemiaNet (ELN) risk classification as a favorable risk factor,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; replacing the &lt;i&gt;CEBPA&lt;/i&gt; double mutations (&lt;i&gt;CEBPA&lt;/i&gt;&lt;sup&gt;dm&lt;/sup&gt;) as favorable marker in the preceding ELN2017 guidelines.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Recent advances in molecular minimal residual disease (MRD) detection in complete remission (CR) have shown profound prognostic value of a selection of AML-specific gene mutations.&lt;span&gt;&lt;sup&gt;5-7&lt;/sup&gt;&lt;/span&gt; However, the prognostic impact of persisting &lt;i&gt;CEBPA&lt;/i&gt; mutations in CR has not been thoroughly investigated in AML patients. Here, we explored the prognostic impact of mutant &lt;i&gt;CEBPA&lt;/i&gt; MRD in a relatively large cohort of 84 AML patients with mutated &lt;i&gt;CEBPA&lt;/i&gt; by deep next-generation sequencing (NGS).&lt;/p&gt;&lt;p&gt;AML patients enrolled in the Dutch-Belgian Cooperative Trial Group for Hematology-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) clinical trials HO42A, HO92, HO102, HO103, and HO132 were included. All trial participants provided written informed consent in accordance with the Declaration of Helsinki, and were treated according to their respective treatment protocol (www.hovon.nl). Patients were assessed for gene mutations on diagnostic bone marrow samples using the TruSight Myeloid Sequencing panel (Illumina) targeting 54 frequently mutated genes in AML.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; Since NGS quality and depth of sequencing of the &lt;i&gt;CEBPA&lt;/i&gt; gene varies when using this gene panel, &lt;i&gt;CEBPA&lt;/i&gt; targeted sequencing was additionally performed on DNA of these diagnostic samples using a custom four-amplicon polymerase chain reaction (PCR) approach (amplicons A, B, C1, C2; Supporting Information: Methods).&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; A total of 144 &lt;i&gt;CEBPA&lt;/i&gt; mutant patients out of 1913 AML cases was identified, of which 84 with available CR samples were included for mutant &lt;i&gt;CEBPA&lt;/i&gt; MRD assessment. Targeted deep sequencing was performed on 100 ng of DNA obtained at CR, after two cycles of standard induction chemotherapy and pretransplant, using the four-amplicon PCR-based NGS approach.&lt;span&gt;&lt;sup&gt;8, 9&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;At diagnosis, 43 out of 84 cases harbored a mutation in the bZIP region (bzip), whereas 41 carried other mutations (non-bzip) (Supporting Information S1: Table 1). All &lt;i&gt;CEBPA","PeriodicalId":12982,"journal":{"name":"HemaSphere","volume":"8 8","pages":""},"PeriodicalIF":7.6,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11326717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
HemaSphere
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1